Novavax (NVAX) Competitors

Novavax (NASDAQ:NVAX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Do insiders & institutionals have more ownership in NVAX or ALKS?

53.0% of Novavax shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 4.9% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor NVAX or ALKS?

Novavax received 152 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 74.11% of users gave Novavax an outperform vote while only 70.51% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Novavax	Outperform Votes 850 74.11%	Underperform Votes 297 25.89%
Alkermes	Outperform Votes 698 70.51%	Underperform Votes 292 29.49%

Do analysts prefer NVAX or ALKS?

Novavax currently has a consensus price target of $17.83, indicating a potential upside of 107.36%. Alkermes has a consensus price target of $36.00, indicating a potential upside of 26.98%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alkermes	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Which has better valuation & earnings, NVAX or ALKS?

Alkermes has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$847.25M	1.63	-$545.06M	-$2.26	-3.81
Alkermes	$1.51B	3.05	$355.76M	$1.95	14.54

Does the media favor NVAX or ALKS?

In the previous week, Novavax and Novavax both had 16 articles in the media. Novavax's average media sentiment score of 0.55 beat Alkermes' score of 0.28 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alkermes	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is NVAX or ALKS more profitable?

Alkermes has a net margin of 22.15% compared to Novavax's net margin of -32.18%. Alkermes' return on equity of 24.92% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-32.18%	N/A	-17.05%
Alkermes	22.15%	24.92%	14.55%

Which has more volatility and risk, NVAX or ALKS?

Novavax has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Summary

Alkermes beats Novavax on 12 of the 17 factors compared between the two stocks.